# Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis

> **NCT00033605** · PHASE3 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 130 (actual)

## Conditions studied

- Cervical Cancer
- Colorectal Cancer
- Diarrhea
- Endometrial Cancer
- Fallopian Tube Cancer
- Ovarian Cancer
- Prostate Cancer
- Sarcoma
- Unspecified Adult Solid Tumor, Protocol Specific
- Vaginal Cancer
- Vulvar Cancer

## Interventions

- **DRUG:** octreotide acetate
- **OTHER:** placebo
- **RADIATION:** radiation

## Key facts

- **NCT ID:** NCT00033605
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2016-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00033605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00033605, "Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00033605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*